In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates. [PDF]
Le Terrier C +4 more
europepmc +1 more source
Hydroxyhexylitaconic acids as potent IMP-type metallo-β-lactamase inhibitors for controlling carbapenem resistance in <i>Enterobacterales</i>. [PDF]
Wachino J-i +6 more
europepmc +1 more source
Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and Pseudomonas aeruginosa. [PDF]
Ferous S +4 more
europepmc +1 more source
Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales. [PDF]
Blanco-Martín T +17 more
europepmc +1 more source
Development and Validation of a Capillary Zone Electrophoresis-Tandem Mass Spectrometry Method for Simultaneous Quantification of Eight β-Lactam Antibiotics and Two β-Lactamase Inhibitors in Plasma Samples. [PDF]
Cizmarova I +3 more
europepmc +1 more source
Related searches:
An Extensive Review on β-lactamase Enzymes and their Inhibitors
Current Medicinal Chemistry, 2023Pritish Varadwaj, Akhilesh Tiwari
exaly
β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources
Pharmaceuticals, 2022Silvana Alfei, Anna Maria Schito
exaly

